Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Da Silva

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
British Journal of Clinical Pharmacology|May 25, 2026
Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosisPaulette Magnas, Naim Bouazza, Frantz Foissac, et al.
American Journal of Respiratory and Critical Care Medicine|February 18, 2021
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary DiseasePierre-Régis Burgel, Isabelle Durieu, Raphaël Chiron, et al.
Mbio|October 24, 2019
The Ancestral N-Terminal Domain of Big Defensins Drives Bacterially Triggered Assembly into Antimicrobial NanonetsKarine Loth, Agnès Vergnes, Cairé Barreto, et al.
Nature Immunology|October 10, 2017
Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetesOphélie Rouxel, Jennifer Da Silva, Lucie Beaudoin, et al.
Cancers|June 10, 2022
Systematic Review of Available CAR-T Cell Trials around the WorldLuciana Rodrigues Carvalho Barros, Samuel Campanelli Freitas Couto, Daniela da Silva Santurio, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 6, 2022
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosisClémence Martin, Martine Reynaud-Gaubert, Rebecca Hamidfar, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 11, 2026
The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in FranceThéo Dhôte, Dominique Grenet, Martine Reynaud-Gaubert, et al.
Clinics (Sao Paulo, Brazil)|August 29, 2024
Custom target-sequencing in triple-negative and luminal breast cancer from young Brazilian patientsPedro Adolpho de Menezes Pacheco Serio, Daniela Marques Saccaro, Ana Carolina Ribeiro Chaves de Gouvêa, et al.
American Journal of Respiratory and Critical Care Medicine|October 12, 2019
Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic FibrosisPierre-Régis Burgel, Anne Munck, Isabelle Durieu, et al.
Annals of the American Thoracic Society|April 5, 2024
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung DiseasePierre-Régis Burgel, Jean-Louis Paillasseur, Isabelle Durieu, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Clinical Pharmacology|May 25, 2026
Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosisPaulette Magnas, Naim Bouazza, Frantz Foissac, et al.
American Journal of Respiratory and Critical Care Medicine|February 18, 2021
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary DiseasePierre-Régis Burgel, Isabelle Durieu, Raphaël Chiron, et al.
Mbio|October 24, 2019
The Ancestral N-Terminal Domain of Big Defensins Drives Bacterially Triggered Assembly into Antimicrobial NanonetsKarine Loth, Agnès Vergnes, Cairé Barreto, et al.
Nature Immunology|October 10, 2017
Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetesOphélie Rouxel, Jennifer Da Silva, Lucie Beaudoin, et al.
Cancers|June 10, 2022
Systematic Review of Available CAR-T Cell Trials around the WorldLuciana Rodrigues Carvalho Barros, Samuel Campanelli Freitas Couto, Daniela da Silva Santurio, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 6, 2022
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosisClémence Martin, Martine Reynaud-Gaubert, Rebecca Hamidfar, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 11, 2026
The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in FranceThéo Dhôte, Dominique Grenet, Martine Reynaud-Gaubert, et al.
Clinics (Sao Paulo, Brazil)|August 29, 2024
Custom target-sequencing in triple-negative and luminal breast cancer from young Brazilian patientsPedro Adolpho de Menezes Pacheco Serio, Daniela Marques Saccaro, Ana Carolina Ribeiro Chaves de Gouvêa, et al.
American Journal of Respiratory and Critical Care Medicine|October 12, 2019
Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic FibrosisPierre-Régis Burgel, Anne Munck, Isabelle Durieu, et al.
Annals of the American Thoracic Society|April 5, 2024
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung DiseasePierre-Régis Burgel, Jean-Louis Paillasseur, Isabelle Durieu, et al.
Pageof 5